Ember Therapeutics, Inc. (EMBT)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2014 | 200.61 Thousand USD | 8.46% |
| 2013 | 184.96 Thousand USD | 13.15% |
| 2012 | 163.46 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2015 Q3 | 214.61 Thousand USD | 2.63% |
| 2015 Q1 | 207.11 Thousand USD | 3.24% |
| 2015 Q2 | 209.11 Thousand USD | 0.97% |
| 2014 Q2 | 195.96 Thousand USD | 4.26% |
| 2014 Q1 | 187.96 Thousand USD | 1.62% |
| 2014 Q3 | 199.46 Thousand USD | 1.79% |
| 2014 FY | 200.61 Thousand USD | 8.46% |
| 2014 Q4 | 200.61 Thousand USD | 0.58% |
| 2013 Q4 | 184.96 Thousand USD | 0.0% |
| 2013 FY | 184.96 Thousand USD | 13.15% |
| 2012 FY | 163.46 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.513% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 95.133% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.27% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.537% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.326% |
| Mesoblast Limited | 118.7 Million USD | 99.831% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 78.844% |
| Genus plc | 233.1 Million USD | 99.914% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 93.154% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 85.069% |
| Marizyme, Inc. | 18.71 Million USD | 98.928% |
| ContraFect Corporation | 2.88 Million USD | 93.037% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 73.251% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -48.07% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 86.129% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 91.375% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 96.455% |
| MultiCell Technologies, Inc. | 202.58 USD | -98930.506% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.651% |
| EV Biologics, Inc. | 1.49 Million USD | 86.579% |
| Q BioMed Inc. | 4.1 Million USD | 95.119% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.394% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 68.16% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 83.668% |
| Biomind Labs Inc. | 735.54 Thousand USD | 72.725% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.883% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 98.456% |
| Skye Bioscience, Inc. | 4.61 Million USD | 95.653% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 77.41% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -41.76% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 96.583% |
| IMV Inc. | 28.88 Million USD | 99.305% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -680.03% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 91.117% |
| GB Sciences, Inc. | 1.75 Million USD | 88.597% |
| Alpha Cognition Inc. | 1.22 Million USD | 83.561% |
| HST Global, Inc. | 98.31 Thousand USD | -104.046% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Halberd Corporation | 150 Thousand USD | -33.744% |
| Enzolytics Inc. | 996.33 Thousand USD | 79.865% |
| Resverlogix Corp. | 6.49 Million USD | 96.909% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 57.986% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 21.509% |
| argenx SE | 20 Million USD | 98.997% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.56% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 92.594% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -1862.015% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.952% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 91.633% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 12.506% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.703% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 93.371% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 44.228% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 99.013% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -34.955% |
| BioStem Technologies, Inc. | 4.71 Million USD | 95.742% |
| ONE Bio Corp. | 19.71 Million USD | 98.982% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 19.812% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 19.341% |
| Agentix Corp. | 50 Thousand USD | -301.232% |
| LadRx Corporation | 33.6 Thousand USD | -496.965% |
| Cell Source, Inc. | 9.25 Million USD | 97.832% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 73.471% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 73.471% |
| NovAccess Global Inc. | 2.19 Million USD | 90.881% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 97.164% |
| Itoco Inc. | 228.37 Thousand USD | 12.156% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | 4.91% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 95.974% |
| Kadimastem Ltd | 891.22 Thousand USD | 77.49% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 50.077% |
| CytoDyn Inc. | 30.07 Million USD | 99.333% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 58.575% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 42.982% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 97.435% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -63.768% |
| Rebus Holdings, Inc. | 310 Thousand USD | 35.285% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 95.763% |
| International Stem Cell Corporation | 4.17 Million USD | 95.198% |
| Bioxytran, Inc. | 1.92 Million USD | 89.578% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -221.433% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 90.801% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 97.588% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 97.663% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 87.103% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 25.143% |
| Neutra Corp. | 54.15 Thousand USD | -270.441% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 89.037% |
| PureTech Health plc | 25.51 Million USD | 99.214% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 83.613% |
| IXICO plc | 472.02 Thousand USD | 57.499% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 98.706% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.678% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Cellectis S.A. | 92.77 Million USD | 99.784% |